Peripheral Blood Mononuclear Cells and Serum Cytokines in Patients with Lupus Nephritis After COVID-19

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2024 Aug 10

PMID 39125849

Authors

Katarzyna A Lisowska

Klaudia Ciesielska-Figlon

Michal Komorniczak

Barbara Bullo-Piontecka

Alicja Debska-Slizien

Anna Wardowska

Affiliations

Soon will be listed here.

Abstract

Systemic lupus erythematosus (SLE) patients have an increased risk of infections and infection-related mortality. Therefore, during the global SARS-CoV-2 pandemic, SLE patients were particularly vulnerable to SARS-CoV-2 infections. Also, compared to other patients, SLE patients seem to develop more severe manifestations of coronavirus disease 2019 (COVID-19), with higher rates of hospitalization, invasive ventilation requirements, or death. This study evaluated the immune parameters after SARS-CoV-2 infection in SLE patients. We analyzed subpopulations of peripheral blood cells collected from patients with renal manifestation of SLE (lupus nephritis, LN). LN patients were divided into two subgroups: those unexposed to SARS-CoV-2 (LN CoV-2(-)) and those who had confirmed COVID-19 (LN-CoV-2(+)) six months earlier. We analyzed basic subpopulations of T cells, B cells, monocytes, dendritic cells (DCs), and serum cytokines using flow cytometry. All collected data were compared to a healthy control group without SARS-CoV-2 infection in medical history. LN patients were characterized by a decreased percentage of helper T (Th) cells and an increased percentage of cytotoxic T (Tc) cells regardless of SARS-CoV-2 infection. LN CoV-2(+) patients had a higher percentage of regulatory T cells (Tregs) and plasmablasts (PBs) and a lower percentage of non-switched memory (NSM) B cells compared to LN CoV-2(-) patients or healthy controls (HC CoV-2(-)). LN patients had a higher percentage of total monocytes compared with HC CoV-2(-). LN CoV-2(+) patients had a higher percentage of classical and intermediate monocytes than LN CoV-2(-) patients and HC CoV-2(-). LN CoV-2(+) patients had higher serum IL-6 levels than HC CoV-2(-), while LN CoV-2(-) patients had higher levels of serum IL-10. LN patients are characterized by disturbances in the blood's basic immunological parameters. However, SARS-CoV-2 infection influences B-cell and monocyte compartments.

References

Quaglia M, Merlotti G, De Andrea M, Borgogna C, Cantaluppi V . Viral Infections and Systemic Lupus Erythematosus: New Players in an Old Story. Viruses. 2021; 13(2). PMC: 7916951. DOI: 10.3390/v13020277. View

Galan M, Vigon L, Fuertes D, Murciano-Anton M, Casado-Fernandez G, Dominguez-Mateos S . Persistent Overactive Cytotoxic Immune Response in a Spanish Cohort of Individuals With Long-COVID: Identification of Diagnostic Biomarkers. Front Immunol. 2022; 13:848886. PMC: 8990790. DOI: 10.3389/fimmu.2022.848886. View

Illescas-Montes R, Corona-Castro C, Melguizo-Rodriguez L, Ruiz C, Costela-Ruiz V . Infectious processes and systemic lupus erythematosus. Immunology. 2019; 158(3):153-160. PMC: 6797874. DOI: 10.1111/imm.13103. View

Sekine T, Perez-Potti A, Rivera-Ballesteros O, Stralin K, Gorin J, Olsson A . Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19. Cell. 2020; 183(1):158-168.e14. PMC: 7427556. DOI: 10.1016/j.cell.2020.08.017. View

Doria A, Canova M, Tonon M, Zen M, Rampudda E, Bassi N . Infections as triggers and complications of systemic lupus erythematosus. Autoimmun Rev. 2008; 8(1):24-8. DOI: 10.1016/j.autrev.2008.07.019. View

Danza A, Ruiz-Irastorza G . Infection risk in systemic lupus erythematosus patients: susceptibility factors and preventive strategies. Lupus. 2013; 22(12):1286-94. DOI: 10.1177/0961203313493032. View

Utrero-Rico A, Ruiz-Ruigomez M, Laguna-Goya R, Arrieta-Ortubay E, Chivite-Lacaba M, Gonzalez-Cuadrado C . A Short Corticosteroid Course Reduces Symptoms and Immunological Alterations Underlying Long-COVID. Biomedicines. 2021; 9(11). PMC: 8614904. DOI: 10.3390/biomedicines9111540. View

Sole C, Domingo S, Vidal X, Cortes-Hernandez J . Humoral and cellular response in convalescent COVID-19 lupus patients. Sci Rep. 2022; 12(1):13787. PMC: 9374301. DOI: 10.1038/s41598-022-17334-5. View

Yurkovich M, Vostretsova K, Chen W, Avina-Zubieta J . Overall and cause-specific mortality in patients with systemic lupus erythematosus: a meta-analysis of observational studies. Arthritis Care Res (Hoboken). 2013; 66(4):608-16. DOI: 10.1002/acr.22173. View

10.

Kuri-Cervantes L, Pampena M, Meng W, Rosenfeld A, Ittner C, Weisman A . Comprehensive mapping of immune perturbations associated with severe COVID-19. Sci Immunol. 2020; 5(49). PMC: 7402634. DOI: 10.1126/sciimmunol.abd7114. View

11.

Taeschler P, Adamo S, Deng Y, Cervia C, Zurbuchen Y, Chevrier S . T-cell recovery and evidence of persistent immune activation 12 months after severe COVID-19. Allergy. 2022; 77(8):2468-2481. PMC: 9347640. DOI: 10.1111/all.15372. View

12.

Caldrer S, Mazzi C, Bernardi M, Prato M, Ronzoni N, Rodari P . Regulatory T Cells as Predictors of Clinical Course in Hospitalised COVID-19 Patients. Front Immunol. 2021; 12:789735. PMC: 8674838. DOI: 10.3389/fimmu.2021.789735. View

13.

Garcia-Cirera S, Calvet J, Berenguer-Llergo A, Pradenas E, Marfil S, Massanella M . Glucocorticoids' treatment impairs the medium-term immunogenic response to SARS-CoV-2 mRNA vaccines in Systemic Lupus Erythematosus patients. Sci Rep. 2022; 12(1):14772. PMC: 9427088. DOI: 10.1038/s41598-022-18996-x. View

14.

Teh C, Wan S, Ling G . Severe infections in systemic lupus erythematosus: disease pattern and predictors of infection-related mortality. Clin Rheumatol. 2018; 37(8):2081-2086. DOI: 10.1007/s10067-018-4102-6. View

15.

Wang H, Lan L, Chen J, Xiao L, Han F . Peripheral blood T-cell subset and its clinical significance in lupus nephritis patients. Lupus Sci Med. 2022; 9(1). PMC: 9386235. DOI: 10.1136/lupus-2022-000717. View

16.

De Biasi S, Meschiari M, Gibellini L, Bellinazzi C, Borella R, Fidanza L . Marked T cell activation, senescence, exhaustion and skewing towards TH17 in patients with COVID-19 pneumonia. Nat Commun. 2020; 11(1):3434. PMC: 7338513. DOI: 10.1038/s41467-020-17292-4. View

17.

Perez-Gomez A, Vitalle J, Gasca-Capote C, Gutierrez-Valencia A, Trujillo-Rodriguez M, Serna-Gallego A . Dendritic cell deficiencies persist seven months after SARS-CoV-2 infection. Cell Mol Immunol. 2021; 18(9):2128-2139. PMC: 8294321. DOI: 10.1038/s41423-021-00728-2. View

18.

Villani A, Satija R, Reynolds G, Sarkizova S, Shekhar K, Fletcher J . Single-cell RNA-seq reveals new types of human blood dendritic cells, monocytes, and progenitors. Science. 2017; 356(6335). PMC: 5775029. DOI: 10.1126/science.aah4573. View

19.

Carvalho J, Dos Reis Neto E, Kakehasi A, Ribeiro S, Studart S, Martins F . Factors associated with poor outcomes in SLE patients with COVID-19: Data from . Lupus. 2022; 32(1):42-53. PMC: 9614598. DOI: 10.1177/09612033221135884. View

20.

Byazrova M, Yusubalieva G, Spiridonova A, Efimov G, Mazurov D, Baranov K . Pattern of circulating SARS-CoV-2-specific antibody-secreting and memory B-cell generation in patients with acute COVID-19. Clin Transl Immunology. 2021; 10(2):e1245. PMC: 7848539. DOI: 10.1002/cti2.1245. View